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This report describes a single-centre study with temozolomide (TMZ) (200mgm
 2day
 1 5 per cycle of 28 days) in children with
(recurrent) high-grade glioma. Magnetic resonance imaging was performed every two cycles. In all, 20 patients were treated between
1998 and 2001 after the UKCCSG/SFOP TMZ phase II trial. All patients had measurable disease. Totally, 15 patients had a relapse
after surgery7radiotherapy7chemotherapy. Overall, five patients received TMZ after surgery or biopsy, awaiting radiotherapy.
There were one clinically malignant grade II glioma, 11 grade III and eight grade IV gliomas. Seven tumours had oligodendroglial
features. Mean age at start of TMZ was 12.0years (range 3–20.5years). In total, eight patients had 48 cycles (range 3–30). One
VGPR (currently in CR after surgery), three PRs (with a PFS of 4, 4 and 11 months, respectively) and one MR (PFS 14 months) were
observed. Three out of five responses occurred after 44 courses. The overall response rate was 20%. Median progression-free
survival (PFS) was 2.0 months (range 3 weeks–34
þ months). PFS rate was 20% after 6 months. Median overall survival (OS) was 10
months. Nine patients showed a clinical improvement. Three patients vomitted shortly after TMZ administration, eight patients (13
cycles) experienced grade III/IV thrombocytopenia, occurring predominantly during the fourth week of the first two cycles. Five
patients experienced neutropenia, and three patients febrile neutropenia. TMZ is a well-tolerated ambulatory treatment for children
with malignant glial tumours. This drug warrants further study in these highly chemoresistant tumours and should be studied either as
upfront therapy or in combination therapy.
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Temozolomide (TMZ) is an oral methylating agent that belongs to
the imidazotetrazine class of drugs. It is metabolised into
monomethyl triazeno imidazole carboxamide (MTIC) (Stevens
et al, 1987), which is also the cytotoxic metabolite of dimethyl
triazeno imidazole carboxamide (DTIC, dacarbazine). The cyto-
toxic effect of MTIC is caused by alkylation of deoxyguanosine
nucleotides, mostly at the O
6 position, leading to DNA mismatch
(G–T match instead of G–C match) (Catapano et al, 1987), DNA
strand breaks and subsequently apoptosis (Tentori et al, 1997).
Several phase I studies with TMZ single drug have been
published in adults and children with solid tumours (Newlands
et al, 1992; O’Reilly et al, 1993; Dhodapkar et al, 1997; Brock et al,
1998; Estlin et al, 1998; Nicholson et al, 1998; Brada et al, 1999),
showing haematological dose-limiting toxicity (DLT). Maximally
tolerated doses (MTD) were between 150 and 250mgm
 2day
 1
when using the once daily oral administration on 5 consecutive
days every 4 weeks, depending on whether or not patients had
been previously treated with nitrosureas (Dhodapkar et al, 1997)
or craniospinal irradiation (CSI) (Nicholson et al, 1998). In
children, the MTD is 180mgm
 2day
 1 for patients with previous
CSI (Nicholson et al, 1998) and 200–215mgm
 2day
 1, respec-
tively for patients without prior CSI (Estlin et al, 1998; Nicholson
et al, 1998, respectively). The reports of phase II trials of
TMZ using comparable administration regimens of 150–
200mgm
 2day
 1 5 every 28 days in adults with recurrent or
progressive grade III or grade IV (oligodendro-) glioma showed
objective response rates varying from 8, 11, 23, 35 and 44%,
respectively (Brada et al, 2001; Bower et al, 1997; Brandes et al,
2001; Yung et al, 1999; Chinot et al, 2001, respectively). A phase II
clinical trial by the UKCCSG New Agents Group/SFOP ‘Groupe de
Pharmacologie’ with this regimen of TMZ in paediatric patients
with recurrent or progressive high-grade glioma showed a lower
response rate of 12% for supratentorial high-grade glioma and 6%
for brainstem glioma, respectively (Lashford et al, 2002). In this
study, the response rate was evaluated after two cycles of TMZ.
Despite the low response rate, several patients improved clinically
suggesting that TMZ is a good palliative treatment in patients with
malignant glioma. We report here a single institution experience
using TMZ in children with (recurrent) grade III or IV glioma,
focussing on clinical improvement, response rate, progression-free
survival (PFS) and toxicity.
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lMATERIALS AND METHODS
Patients
The inclusion period of our study (from May 1998 to February
2001) started after the accomplishment of the UKCCSG/SFOP New
Agents Group TMZ phase II trial. Patients of 1–21years of age
were eligible with grade III or grade IV glioma, including high-
grade oligodendroglioma. Patients with brainstem glioma were
excluded. Histology was evaluated centrally.
In all, 15 patients were included in the study population while
showing a recurrence or progression after neurosurgery7ra-
diotherapy7chemotherapy. Prior chemotherapy within the last 4
weeks was an exclusion criteria. Five patients received TMZ at
initial diagnosis while awaiting radiotherapy after having had a
resection or a biopsy. Patients’ characteristics are mentioned in
Table 1. All patients had measurable disease.
Drug administration and assessment of response and
toxicity
TMZ (Temodal
s, 200mgm
 2day
 1 orally) was administered once
a day on 5 consecutive days per cycle of 28 days. Ingestion
occurred in the morning 30min before breakfast. In case of grade I
(or more) nausea or vomiting, ondansetron was administered
30min before the administration of TMZ. The dose of TMZ was
decreased by 20% for the subsequent cycle in case of repeated or
prolonged (47 days) grade III/IV haematological toxicity. This
dose decrement could be repeated for subsequent cycles.
Magnetic resonance imaging was performed prior to the start of
TMZ treatment and was repeated every two cycles. All imaging was
reviewed to determine any response. Response criteria were according
to WHO (WHO, 1979), using the product of the two maximal dia-
meters of the tumour. Best response was determined at any evaluation
moment during the treatment period. Treatment was continued in case
o fm i n o r ,p a r t i a lo rc o m p l e t er e s p o n s eo rs t a b l ed i s e a s e .P r o g r e s s i o n -
free survival was defined as the interval between the first day of the first
cycle of TMZ and the occurrence of tumour progression.
Toxicity was assessed according to the NCI-CTC. Full blood
count was analysed once a week and once to twice a week during
the third and fourth week of each cycle. Thrombocyte transfusions
were administered when platelet count dropped below 50 10
9l
 1.
RESULTS
Totally, 20 patients were treated between May 1998 and May
2001. Follow-up was until May 2002. Patients’ characteristics
Table 1 Patients’ characteristics and outcome of the study population
Patient
no.
Histology
nominal
Histology
grade
Therapy
before TMZ
Status
before
relapse Metastasis
Age at
start
TMZ
(years) Corticosteroids?
Clinical
improvement Response
PFS
(months)
1 Oligodendroglioma II CH+RT PD Y 6.9 Y (See text) VGPR 34+
2 Glioblastoma IV SU+RT+CH VGPR I N 9.9 N Hemiplegia – PR 11
seizures –
3
a Malignant glioma IV SU PR I N 15.8 Y Corticosteroids – PR 4
4 Anaplastic
oligodendroglioma
III CH PD Y 9.5 N Hemiplegia –
seizures –
MR 14
vomiting –
5 Anaplastic glioma IV SU+RT+CH PR I Y 8.1 Y No PD 0.75
6 Gemistiocytic
astrocytoma
III SU+CH+SU+SU+RT PR 2 Y 3 N No PD 0.75
7 Anaplastic
oligodendroglioma
III SU+CH+CH+RT+SU CR 3 N 5.7 N No PD 2
8 Malignant glioma IV SU+RT PR 2 Y 18.2 N No PD 1.5
9 Anaplastic
oligodendroglioma
III SU+RT+CH PR 1 N 14.7 N No PD 1.5
10 Malignant glioma IV SU+RT PR 2 N 18.9 Y No PD 2
11
a Anaplastic
ganglioglioma
III SU PR 1 N 9.5 N No PD 1
12
a Astrocytoma III N 9.5 Y No PD 2
13 Medullary
glioblastoma
IV SU+SU+RT CR 5 N 18.7 N No PD 2
14 Gemistocytic
astrocytoma
III SU+RT PR Y 17 Y Briefly improved
swallowing
PD 2
15
a Malignant glioma IV SU PR N 6.9 Y Hemiplegia – PD 2.5
diplopia –
corticosteroids –
16 Anaplastic
oligodendroglioma
III SU+RT+CH CR N 13.9 N No PR 4
17
a Anaplastic
oligodendroglioma
III N 8.8 N Hemiplegia – PD 3.5
18 Glioblastoma IV SU+RT PR Y 20.5 N No PD 2
19 Oligodendrocytoma III SU+RT+CH+CH+RT
+CH+RTCHIR
PR 5 N 10.1 Y Hemiplegia –
vomiting –
PD 2
corticosteroids –
20 Astroblastoma III CH+CH+SU+CH+RT PR 2 N 14.1 Y Hemiplegia – PD 7
vomiting –
corticosteroids –
aPatients were treated prior to radiotherapy. RT¼radiotherapy; SU¼surgery; Ch¼chemotherapy; VGPR¼very good partial response; PR¼partial response; MR¼minor
response; PD¼progressive disease. A – sign in the ‘clinical improvement’ column means that the symptom disappeared or corticosteroid therapy was weaned.
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lare shown in Table 1. Seven patients had metastatic disease
and nine patients were on corticosteroid therapy when starting
TMZ treatment. Eight patients had a relapse after surgeryþ
radiotherapyþchemotherapy, five patients after surgeryþ
radiotherapy, one patient after chemotherapyþradiotherapy,
and one patient after chemotherapy alone. Three patients
received TMZ after incomplete resection and two patients after
having had a biopsy only, awaiting radiotherapy. Of these 18
patients, response to prior therapy was CR for three patients
(one CR1, one CR3, one CR5), one VGPR, 12 PR (seven PR1,
four PR2, one PR5) and two PD. Mean age at start of TMZ was
12.0 year (range 3–20.5 year). Median number of cycles was 2.0
(range 1–30
þ).
We observed one VGPR (currently in CR after surgery),
and three PRs (with a PFS of 4, 4 and 11 months, respectively)
and one MR (PFS 14 months). Three of the five responses were
observed in oligodendroglioma. Three out of five responses
occurred after 44 courses. Median PFS was 2.0 months (range 3
weeks–34 months
þ). The overall response rate (CRþPR) was
20% (95% CI 2–38%). PFS rate was 20% after 6 months
(Figure 1A). Median overall survival was 10 months (Figure 1B).
Nine patients showed a clinical improvement (Table 1); 50%
of the patients on corticosteroid therapy could reduce or stop
corticosteroids.
Two patients experienced a clinical deterioration during the first
cycle of TMZ, while they improved clinically and radiologically
during the subsequent courses.
Three patients vomitted shortly after TMZ administration. Eight
patients experienced grade III/IV thrombocytopenia: platelet nadir
could not be determined since the patients received platelet
transfusions (total of 23 transfusions in 13 cycles) when platelet
counts dropped below 50 10
9l
 1. A large majority of thrombo-
cytopenic events occurred during the fourth week of the TMZ
cycles. Seven out of eight patients experienced thrombocytopenia
during the first two cycles. Five patients (one cycle each) developed
neutropenia (four of which during the first cycle), and three
patients febrile neutropenia. Doses of TMZ were reduced in three
patients. There was no treatment-related mortality.
Of the five patients that were treated prior to radiotherapy, one
patient responded (patient 3).
The patient with the best response (VGPR and currently in
CR after surgery, patient 1) was initially diagnosed as having a
low-grade oligodendroglioma. The tumour was inoperable, and
the patient received two courses of etoposide 500mgm
 2
and carboplatin 800mgm
 2, after which he progressed. Subse-
quently, the patient received local irradiation with 55Gy, after
which he still progressed with even leptomeningeal dissemination.
The predominant localisations of the tumour were the right
temporal lobe and the thalamus. Owing to this rapid and clinically
malignant evolution in 6 months, we judged that the clinical
behaviour of the tumour was more compatible with a high-grade
glioma. Therefore, we started TMZ treatment, leading to a PR after
six courses, a VGPR after 16 cycles and subsequently a CR after
surgery. At the start of TMZ treatment he presented with a left-
sided haemiplegia and facial nerve palsy, coordination and
behavioural abnormalities and seizures, and required
1.5mgkg
 1day
 1 of prednisolone. After initial improvement after
two courses of TMZ, a clinical deterioration was observed after the
fourth course which was probably due to an intratumoural
haemorrhage, requiring a temporary increase in corticosteroid
dose. Subsequently, his clinical condition reimproved and after
eight courses of TMZ, corticosteroid therapy could be stopped,
while only a minor pyramidal tract syndrome persists. He
currently has normal school activities and plays basketball.
Although the clinical behaviour and radiological features of
the tumour were in favour of a high-grade glioma, central
histological review confirmed the initial histological diagnosis of
low-grade glioma.
DISCUSSION
The 20% objective response rate as observed in our series is
slightly better than the results of the British/French collaborative
paediatric study group, reporting a response rate of 12 and 6% in
high-grade glioma and brainstem glioma, respectively (Lashford
et al, 2002). Our study reports the best response at any moment
during TMZ treatment, while in the French/British study the
response was evaluated after two cycles of TMZ. The reports of the
various phase II TMZ studies performed in adults with recurrent
malignant glioma using comparable dosing regimens as used in
our study describe a broad spectrum of activity. The response rates
of each phase II study cannot be completely compared since
response was not evaluated after the same number of cycles of
TMZ. Since responses may be delayed, evaluation of best response
will lead to a higher response rate as compared to response
evaluation after two cycles. The best results were reported in a
population of adult patients with anaplastic oligodendroglioma or
anaplastic oligoastrocytoma (Chinot et al, 2001), showing CR in
17% and PR in 27% of the patients. High-grade oligodendroglial
tumours are considered as chemoresponsive (Glass et al, 1992) to
combination regimens like PCV (procarbazine, CCNU, vincris-
tine). In our study population, seven out of 20 tumours (35%, 95%
CI 12–58%) had oligodendrial features, whose proportion may
appear high. Only a small minority of glial tumours consist of
oligodendroglioma (Jukich et al, 2001), although percentages of
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Figure 1 Progression-free survival (A) and overall survival (B) of the
total study population as determined from the start of temozolomide
treatment for each patient. ’ Symbols represent censored observations.
Median PFS was 2 months. Median OS was 10 months.
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l33% have been described in adults in a series (Daumas-Duport
et al, 1997). Owing to the small numbers of patients in our series,
the proportion of oligodendroglioma should be interpreted with
caution. Moreover, due to the small numbers it is difficult to
demonstrate a more pronounced effect in the patients with
oligodendroglioma (one VGPR, one PR and one MR out of seven
patients) as compared to the other glial tumours (two PR out of 13
patients). Not only oligodendroglial tumours respond to TMZ, as
was demonstrated by Yung et al (1999), who reported a response
rate of 35% and disease stabilisation in 26% of their series of
predominantly anaplastic astrocytoma. These response rates are
higher as compared with our results that are more comparable
with the response rates of 11 and 23%, respectively as observed in
other phase II trials in high-grade glioma (Bower et al, 1997;
Brandes et al, 2001). Even if the reported response rates of the
various clinical trials are not homogeneously high, we must
consider that TMZ is one of the few drugs that have shown activity
as single drug in high-grade glioma. Evidence of single drug
activity has to our knowledge only been demonstrated for
nitrosureas, such as BCNU and CCNU (Walker et al, 1978, 1980;
Solero et al, 1979) and high-dose cyclophosphamide (McCowage
et al, 1998) that are drugs with non-neglectable toxicity.
Therefore, the reported response rates of TMZ as single drug
should lead to future applications of TMZ in combination with
other treatment modalities or using a different dosing schedule of
TMZ as single drug. Regarding the latter, a phase I trial with an
over 7-week protracted schedule of TMZ, showed an acceptable
tolerance at a daily dose of 75mgm
 2day
 1 (Brock et al, 1998),
while increasing two-fold the systemic exposure as compared to
the 200mgm
 2day
 1 5 per 28-day schedule. A comparable
ongoing phase I study in a Canadian paediatric population seems
to confirm this observation (Baruchel et al, 2002). The results of a
phase II trial with a comparable schedule in adults with relapsed
malignant glioma proved not successful (Khan et al, 2002).
However, this regimen may be suitable for combination with
radiotherapy in newly diagnosed high-grade glioma. Several phase
II studies with radiotherapy and TMZ are currently ongoing
or have recently been completed in adults with glioblastoma
multiforme (Yung et al, 2001). A more protracted regimen may
also be attractive for the treatment of acute leukaemia, since TMZ
may have some activity in this pathology as well (Seiter et al, 2001).
Various other dosing schedules of TMZ have been studied, trying
to increase the systemic exposure while not increasing the toxicity
(Yung et al, 2001). The 300mgm
 2day
 1 3 per 2week regimen
is likely to increase the systemic exposure as compared with the
regimen we used, and showed a response rate of 30% in primary
glioma (Raymond et al, 2002).
Several phase I and II clinical trials combining TMZ with other
cytotoxic drugs are ongoing or have been completed. The
combination with carmustine (IV or polifeprosan implants) may
be promising in high-grade glioma (Schold et al, 2000; Prados,
2001). A phase I trial with TMZ and cisplatin in adults resulted in a
MTD of TMZ 200mgm
 2day
 1 for 5 days and cisplatin 75mgm
 2
on day 1 of a 28-day cycle (Britten et al, 1999). Recently, a similar
study with TMZ and cisplatin was performed among paediatric
patients with recurrent intracranial and extracranial solid tumours
by the Pharmacology Group of the French Pediatric Oncology
Society (SFOP) (Vassal et al, manuscript in preparation). Finally,
the combination of CPT-11 (irinotecan) and TMZ is being studied
in phase I trials in adults with recurrent high-grade glioma
(Prados, 2001). The rationale of this combination is based on
preclinical studies describing a synergistic effect on xenografts
models of human glioma and paediatric solid tumours (Houghton
et al, 2000; Patel et al, 2000). Striking are the complete responses
that were observed in neuroblastoma, rhabdomyosarcoma and
glioblastoma multiforme in these preclinical studies (Houghton
et al, 2000), making the combination of TMZ and CPT-11 also
attractive for clinical trials in paediatric extracranial tumours.
In conclusion, some patients with high-grade glioma may
stabilise or respond to a treatment with TMZ, which should be
administered 4two cycles (unless significant deterioration) since
responses may be delayed. Almost 50% of the patients in our series
experienced clinical improvement. TMZ is a well-tolerated
ambulatory treatment for children with (relapsed) malignant glial
tumours and should be combined with other treatment modalities
in future clinical trials in CNS tumours.
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